Liminal BioSciences IncNASDAQ:LMNL
- LAST PRICE3.8000
- TODAY'S CHANGE (%)0.2900 (8.2621%)
- Bid / Lots3.1000/ 10
- Ask / Lots5.4300/ 3
- Open / Previous Close3.8000 / 3.5100
- Day Range
- 52 Week Range
- Volume271
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LMNL |
|---|---|---|
| 02:15 ET | 100 | 3.8 |
Mar 15, 2023
BRIEF-Liminal Biosciences Reports Q4 And Year Ended 2022 Financial Results, from 4:09PM ET on Wednesday Mar 15, 2023 by Thomson Reuters
4:09PM ET on Wednesday Mar 15, 2023 by Thomson ReutersLiminal BioSciences Reports Fourth Quarter and Year Ended 2022 Financial Results, from 4:05PM ET on Wednesday Mar 15, 2023 by PR Newswire
4:05PM ET on Wednesday Mar 15, 2023 by PR Newswire
Mar 13, 2023
Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023, from 4:05PM ET on Monday Mar 13, 2023 by PR Newswire
4:05PM ET on Monday Mar 13, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Liminal BioSciences Inc | 11.8M | -0.5x | --- |
Halberd Corp | 8.5M | 6.5x | --- |
Navidea Biopharmaceuticals Inc | 8.5M | -0.5x | --- |
Virax Biolabs Group Ltd | 8.9M | -4.6x | --- |
Minerva Neurosciences Inc | 8.5M | -0.3x | --- |
Context Therapeutics Inc | 9.0M | -0.6x | --- |
Company Information
Liminal BioSciences Inc. is a Canada-based development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
Contact Information
- Headquarters
- 231 Dundas Street EastBELLEVILLE, ON, Canada K8N 1E2
- Phone
- 450-781-0115
- Fax
- 450-781-4477
Executives
- Independent Chairman of the Board
- Aleksander Krstajic
- President
- Patrick Sartore
- Chief Executive Officer
- Bruce Pritchard
- Interim Chief Financial Officer
- N. Nicole Rusaw
- General Counsel
- Marie Iskra
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.8M |
|---|---|
Revenue (TTM) | $296.7K |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-6.92 |
Book Value | $8.63 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 39.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8,223.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
